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Oncolytic adenovirus co-expressing IL-12 and IL-18
improves tumor-speciﬁc immunity via differentiation
of T cells expressing IL-12Rb2 or IL-18Ra
I-K Choi1, J-S Lee2, S-N Zhang2, J Park2, K-M Lee4, CH Sonn4 and C-O Yun1,2,3
The oncolytic adenovirus (Ad) is currently being advanced as a promising antitumor remedy as it selectively replicates in tumor
cells and can transfer and amplify therapeutic genes. Interleukin (IL)-12 induces a potent antitumor effect by promoting natural
killer (NK) cell and cytotoxic T cell activities. IL-18 also augments cytotoxicity of NK cells and proliferation of T cells. This
effect further enhances the function of IL-12 in a synergistic manner. Therefore, we investigated for the ﬁrst time an effective
cancer immunogene therapy of syngeneic tumors via intratumoral administration of oncolytic Ad co-expressing IL-12 and IL-18,
RdB/IL-12/IL-18. Intratumoral administration of RdB/IL-12/IL-18 improved antitumor effects, as well as increased survival, in
B16-F10 murine melanoma model. The ratio of T-helper type 1/2 cytokine as well as the levels of IL-12, IL-18, interferon-g and
granulocyte–macrophage colony-stimulating factor was markedly elevated in RdB/IL-12/IL-18-treated tumors. Mice injected with
RdB/IL-12/IL-18 also showed enhanced cytotoxicity of tumor-speciﬁc immune cells. Consistent with these results, immense
necrosis and inﬁltration of NK cells, as well as CD4+ and CD8+ T cells, were observed in RdB/IL-12/IL-18-treated tumor tissues.
Importantly, tumors treated with RdB/IL-12/IL-18 showed an elevated number of T cells expressing IL-12Rb2 or IL-18Ra. These
results provide a new insight into therapeutic mechanisms of IL-12 plus IL-18 and provide a potential clinical cancer
immunotherapeutic agent for improved antitumor immunity.
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INTRODUCTION
Over the past decade, tumor immunology has advanced in uncovering
the molecular and cellular mechanisms responsible for cancer patho-
physiology and for enhancing the immune response against tumors,
yet there are still many unresolved problems concerning which tumors
can escape, or suppress, the immune response. Therefore, immuno-
therapy for malignant diseases needs novel, improved clinical proto-
cols that minimize tumor-induced immunological tolerance while
simultaneously inducing tumor eradication. One potential strategy
is a cytokine immunogene therapy that has a great potential for
rejecting cancer cells by activating tumor-speciﬁc immune responses
in cancer-bearing hosts.
Interleukin (IL)-12 is one of the most effective and promising
antitumor cytokines. It is a heterodimeric cytokine composed of two
different disulﬁde-linked subunits, designated p35 and p40, and is
mainly produced by activated macrophages and dendritic cells (DCs).
IL-12 stimulates interferon-g (IFN-g) production by natural killer
(NK) cells, T cells, DCs and macrophages. Similarly, it facilitates
T helper type 1 (Th1) differentiation and augments the cytolytic effect
of NK cells and cytotoxic T lymphocytes (CTLs). Previous preclinical
studies of IL-12 reported enhanced antitumor immunity.1,2 More
recently, we showed an enhanced antitumor effect of an oncolytic
adenovirus (Ad) that expresses both IL-12 and B7-1 in a murine
melanoma B16-F10 tumor model.3
IL-18, IFN-g-inducing factor, is secreted mainly by activated
macrophages and DCs.4 IL-18 plays a signiﬁcant role in cell-mediated
immune responses and is capable of generating an antitumor immune
response via induction of IFN-g production from,5,6 enhancing the
cytotoxicity of,4,7 and stimulating the proliferation of T and NK
cells.6,8 Several studies have shown the antitumor efﬁcacy of IL-18
in murine tumor models. For example, IL-18 exerted antitumor
immunity by activating NK cells and establishing cytotoxic CD4+
T cells in Meth A sarcoma-bearing mice.9 In addition, IL-18 was
also shown to be a potent adjuvant, enhancing systemic antitumor
immune responses and vaccine efﬁcacy.10 Therefore, IL-18 represents a
promising therapeutic candidate for cancer immunogene therapy.
Previous studies reported that IL-18 is able to drive the Th2 immune
response in an IL-4-dependent manner, but induces a Th1 immune
response in the presence IL-12.11,12 These results suggest that IL-18 alone
could suppress the Th1 immune response via activation of Th2 immune
response. Therefore IL-18, acting in concert with IL-12, may be
important in effective immunotherapy. Consistent with this suggestion,
an earlier study reported that IL-12 plus IL-18 polarized Th1 immunity,
resulting in the generation of potent tumor-reactive T cells.13 This
combination also enhanced the cytolytic effect as well as IFN-g produc-
tion from T and NK cells, as well as the proliferation in T cells.11,14
Furthermore, previous studies reported that IL-12 in combination with
IL-18 inhibited tumor angiogenesis, leading to tumor regression.15
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www.nature.com/gtIn this study, we show for the ﬁrst time an effective cancer
immunogene therapy of syngeneic tumors via intratumoral adminis-
tration of oncolytic Ad co-expressing IL-12 and IL-18. We also show
the underlying mechanism of oncolytic Ad co-expressing IL-12 and
IL-18, showing that antitumor immunity is associated with elevation
of Th1/Th2 cytokine ratio and upregulation of IL-12, IL-18, IFN-g
and granulocyte–macrophage colony-stimulating factor (GM-CSF)
within the tumor tissues. Moreover, we show that the induction of
an optimal tumor milieu, generating effective tumor-speciﬁc immu-
nity through the upregulation of Th1 cytokines, enhances the genera-
tion of fully differentiated T cells expressing IL-12Rb2o rI L - 1 8 R a.
RESULTS
Generation of oncolytic Ad-mediated IL-12 and IL-18
Three oncolytic Ads expressing IL-12 alone, IL-18 alone, or IL-12 and
IL-18 were generated in the E1B-deleted and E1A-mutated oncolytic
Ad, oncolytic Ad vector, Ad-DE1Bmt7 (RdB) (Figure 1a). To conﬁrm
IL-12 and IL-18 secretion from these Ads, B16-F10 melanoma cells
were infected with RdB, RdB/IL-12, RdB/IL-18, or RdB/IL-12/IL-18 at
various multiplicity of infections (MOIs), and culture supernatants
were obtained 96h after infection to examine IL-12 and IL-18
production. A dose (MOI)-dependent increase in IL-12 and IL-18
expression was observed in the cells infected with RdB/IL-12,
RdB/IL-18 or RdB/IL-12/IL-18 at different MOIs (Figures 1b and c).
Interestingly, the addition of IL-12 or IL-18 seemed to adversely affect
the expression of either cytokine induced by oncolytic Ad. Both RdB/
IL-12 and RdB/IL-18 induced higher IL-12 and IL-18 expression
compared with RdB/IL-12/IL-18. Speciﬁcally, the expression of IL-12
and IL-18 from RdB/IL-12 (100MOI) and RdB/IL-18 (200MOI) were
43428±797 and 1150±68, respectively, whereas those from RdB/IL-
12/IL-18 were 13468±48 and 445±8, showing about a threefold
decrease in cytokine expression.
To further investigate whether IL-12, IL-18, or IL-12 plus IL-18
expression would alter viral replication, RdB/IL-12, RdB/IL-18 or
RdB/IL-12/IL-18 were evaluated for their capability to induce viral
cytopathic effects in a variety of cell lines. Because murine cells tend to
be less sensitive or even resistant to Ad infection compared with
human cells, we employed three different types of human cancer cell
lines (U343, C33A and A549) from varying histological types. Cells
were infected with RdB (cognate oncolytic Ad), RdB/IL-12, RdB/IL-18
or RdB/IL-12/IL-18, along with Ad-DE1 as a negative control. The
cells were then treated with crystal violet to show the relative extent of
cell lysis. RdB/IL-12, RdB/IL-18 and RdB/IL-12/IL-18 generated cyto-
pathic effects equivalent to RdB alone in all cell lines tested, showing
that IL-12, IL-18, or IL-12 plus IL-18 expression does not decrease the
viral replication ability of oncolytic Ad (Supplementary Figure 1).
Figure 1 Characterization of adenovirus (Ad) vectors used in this work. (a) Schematic representations of the IL-12 or IL-18 gene inserted into the E3 region
of RdB, respectively. RdB/IL-12/IL-18 is comprised of the IL-12 and IL-18 genes in the E1 and E3 region of RdB, respectively (asterisk indicates mutation
at Rb binding site of E1A). (b, c) Expression of IL-12 (b) and IL-18 (c). The concentration of cytokines was measured in the culture supernatants 96h after
infection by ELISA. Mean values and s.e.m. of three or more experiments, each performed in triplicate, are shown.
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To ascertain whether RdB/IL-12, RdB/IL-18 or RdB/IL-12/IL-18
induced the suppression of tumor growth in syngeneic mice, we
injected 5 105 cells of B16-F10 melanoma subcutaneously into
C57BL/6 mice. When the tumor volume averaged 80mm3, mice
were injected intratumorally with phosphate-buffered saline (PBS),
RdB, RdB/IL-12, RdB/IL-18 or RdB/IL-12/IL-18 once every other day
for a total of three injections. As presented in Figure 2a, control
tumors treated with PBS showed aggressive growth, leading to a
tumor volume of 3997.1±412.2mm3 14 days after viral treatment.
In marked comparison, RdB/IL-12-, RdB/IL-18- and RdB/IL-12/
IL-18-treated tumors reached an average volume of 202.4±43,
1009±181.7 and 26.5±10.3mm3, respectively, showing 95% (RdB/
IL-12), 75% (RdB/IL-18) and 99% (RdB/IL-12/IL-18) tumor growth
inhibition compared with PBS control (Po0.05). By day 20 following
treatment, tumor re-growth was observed in RdB/IL-18- and RdB/
IL-12-treated tumors, showing 3946.7±817.8 and 960.1±349.3mm3,
respectively, whereas those treated with RdB/IL-12/IL-18 maintained
inhibition of tumor growth (145±64.7mm3)( Po0.01). Moreover,
RdB/IL-12/IL-18 elicited more prolonged suppression of tumor
growth than RdB/IL-12 (Po0.01) (Supplementary Figure 2). Further-
more, RdB/IL-12/IL-18-treated mice showed higher survival rates
compared with either RdB/IL-12 or RdB/IL-18 (Po0.01). All animals
treated with RdB/IL-12/IL-18 remained viable 28 days after the
beginning of the treatment, whereas only 16.7% of those treated
with RdB/IL-18 and 50% of those treated with RdB/IL-12 survived for
the same period of time (Figure 2b). Taken together, these results
suggest that RdB/IL-12/IL-18 signiﬁcantly prolonged survival and
enhanced antitumor efﬁcacy compared with either RdB/IL-12 or
RdB/IL-18 in the B16-F10 murine melanoma model.
In vivo oncolytic Ad treatment increased local expression of IL-12,
IL-18, IFN-c and GM-CSF
To determine the amount of IL-12 and IL-18 produced in RdB/IL-12-,
RdB/IL-18- or RdB/IL-12/IL-18-treated mice, tumor tissues were
harvested 3 days following the last viral injection. As seen in Figures
3a and b, a minimal amount of IL-12 was observed in the tumors
treated with PBS, RdB or RdB/IL-18. In contrast, tumors treated with
RdB/IL-12 or RdB/IL-12/IL-18 showed high concentrations of IL-12
(57.3±6.6pgmg 1 for RdB/IL-12 and 213.6±9.9pgmg 1 for RdB/
IL-12/IL-18, Po0.05) (Figure 3a). Similarly, RdB/IL-18- or RdB/
IL-12/IL-18-treated tumors produced signiﬁcantly higher levels of
IL-18 (61±1.8pgmg 1 for RdB/IL-18 and 213.4±27.1pgmg 1 for
RdB/IL-12/IL-18) than did those treated with PBS, RdB or RdB/IL-12
(18.6±3.3, 14.3±2.9 and 20.4±3.1pgmg 1, respectively, Po0.05)
(Figure 3b). Interestingly, IL-12 and IL-18 levels in tumor tissues
treated with RdB/IL-12/IL-18 were synergistically greater than those
treated with RdB/IL-12 or RdB/IL-18 in vivo,e v e nt h o u g hin vitro,
IL-12 and IL-18 levels from RdB/IL-12/IL-18-treated cells were much
lower than those of either RdB/IL-12- or RdB/IL-18-treated cells.
Given that IL-12 and IL-18 can act synergistically to enhance the
production of IFN-g and GM-CSF from T and NK cells,11,13,14 we
examined IFN-g and GM-CSF production in the RdB/IL-12/IL-18-
treated tumor tissue. As shown in Figure 3c and d, PBS-, RdB- and
RdB/IL-18-injected mice showed relatively low levels of IFN-g
(342.6±54.6, 179.2±80.7 and 391.2±159.7pgmg 1, respectively).
In comparison, RdB/IL-12- or RdB/IL-12/IL-18-injected tissue showed
high levels of IFN-g (2364.4±265.4pgmg 1 for RdB/IL-12 and
3590.6±213.5pgmg 1 for RdB/IL-12/IL-18, Po0.05) (Figure 3c).
In addition, RdB/IL-12/IL-18-treated tissue showed the highest
GM-CSF expression (27.7±4.7pgg 1) compared with PBS- (2.5±
4.7pgg 1), RdB- (3.9±1.4pgg 1), RdB/IL-12- (8.5±0.6pgg 1)a n d
RdB/IL-18-treated tumor tissue (6.8±1.4pgg 1) (Figure 3d). These
results show that RdB/IL-12/IL-18-treated tumors produced signiﬁ-
cantly higher amounts of IL-12, IL-18, IFN-g and GM-CSF than any
of the other groups.
Increase of Th1/Th2 cytokine ratio
An aberrant Th1/Th2 cytokine balance with elevated Th2 cytokine
levels, which favors development and progression of cancers, was
found in various tumor-bearing patients, and a correlation between
cytokine levels and the efﬁcacy of cancer treatments has also been
reported.16,17 Hence, we further investigated whether RdB/IL-12/IL-
18, which produced markedly higher amounts of Th1 cytokines
(IFN-g and GM-CSF) than any of the other groups, could converse
from Th2 immunity toward Th1 immunity in tumor tissues. Tumor
tissues from mice at 3 days following the ﬁnal viral injection were
harvested and analyzed with Th1/Th2/Th17 cytometric bead assay
(CBA) kit (BD Biosciences PharMingen, San Diego, CA, USA). As
IL-2, IL-4, IL-10 and IL-17 were not detected in the tumor tissues of
all groups (data not shown), the ratio of Th1/Th2 cytokine was
Figure 2 Antitumor effects and survival rate of tumor-bearing mice.
Antitumor (a) and survival rate (b) in mice given PBS (}), RdB (&), RdB/
IL-18 (E), RdB/IL-12 (’) or RdB/IL-12/IL-18 ( ). C57BL/6 tumor-bearing
mice were treated with intratumoral injections of 1 108 plaque-forming unit
per 30ml of Ads on days 0, 2 and 4. Tumor volume was monitored on a
2-day interval until the end of the study. The arrow represents Ad
inoculation. Values represent the mean±s.e.m. (6 animals per group). RdB/
IL-12/IL-18-treated mice showed signiﬁcantly enhanced antitumor effects
and higher survival rates than did RdB/IL-12-treated mice. **Po0.01 vs
RdB/IL-12-treated group.
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(TNF-a)/IL-6. As presented in Figure 4, RdB/IL-12/IL-18-treated
tumor tissue exhibited the highest IFN-g/IL-6 and TNF-a/IL-6 ratio
value compared with PBS-, RdB-, RdB/IL-12- or RdB/IL-18-treated
tumor tissue (Po0.01), suggesting that RdB/IL-12/IL-18 polarizes
T cell responses toward the type 1 pattern by enhancing Th1 cytokine
and suppressing Th2 cytokine in the tumor microenvironment.
Generation of a tumor-speciﬁc immune response
Results from enzyme-linked immunosorbent assay (ELISA) and CBA
assay in tumor tissues indicate that RdB/IL-12/IL-18 might generate
a tumor microenvironment that is more favorable to activate
tumor-speciﬁc immune cells than an oncolytic Ad expressing either
IL-12 or IL-18 alone. Therefore, we examined whether RdB/IL-12/IL-18
could enhance immune responses in vivo by assessing the number of
immune cells expressing IFN-g, a cytokine secreted by activated
T cells. Splenocytes from mice at 3 days following the ﬁnal viral
injection were harvested and co-cultured with irradiated B16-F10
tumor cells for 3 days in the presence of recombinant human IL-2.
Co-cultured splenocytes were serially seeded into the IFN-g ELISPOT
plate at concentrations from 2.5 104 to 1 106 cells per well and the
number of IFN-g-secreting cells was determined. As shown in
Figure 5a, the frequency of IFN-g-secreting immune cells recovered
from mice injected with RdB/IL-12/IL-18 was signiﬁcantly greater than
Figure 3 RdB/IL-12/IL-18 treatment increased local expression of IL-12, IL-18, IFN-g and GM-CSF in vivo. Tumor tissue was obtained 3 days after ﬁnal viral
treatment. ELISA was carried out to estimate the level of IL-12 (a), IL-18 (b), IFN-g (c) and GM-CSF (d) in tumor tissues. Experiments were performed in
triplicate and repeated three times. Each data point indicates means±s.e.m. of IL-12, IL-18, IFN-g and GM-CSF levels for each individual tumor. RdB/
IL-12/IL-18 produced a synergistically higher levels of IL-12, IL-18, IFN-g and GM-CSF than RdB/IL-12 or RdB/IL-18 (Wilcoxon’s signed-rank *Po0.05
compared with the sum of RdB/IL-12 or RdB/IL-18 alone).
Figure 4 Increased Th1/Th2 cytokine ratio in tumor tissue treated with RdB/IL-12/IL-18. Tumor tissue was harvested 3 days after last viral injection.
Th1/Th2/Th17 CBA assay was performed to determine the Th1/Th2 cytokine ratio in tumor tissues. (a)I F N - g/IL-6 ratio. (b) Tumor necrosis factor-a/IL-6 ratio.
Each data point indicates mean value±s.e.m. of triplicates of representative of three independent experiments. **Po0.01 vs RdB/IL-12-treated group.
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Gene TherapyFigure 5 Generation of a tumor-speciﬁc immune response. Subcutaneous tumors derived from B16-F10 cells were inoculated with RdB, RdB/IL-12,
RdB/IL-18 or RdB/IL-12/IL-18 along with PBS as a negative control. Ad-treated mice were killed 3 days following last administration, and IFN-g ELISPOT
and 51Cr-release assays were carried out. (a) Examples of spot-forming cell (SFC) response. (b) ELISPOT assay for IFN-g. The number of spots counted at a
concentration of 2.5 105. Each value represents the mean spot number±s.e.m. of triplicates of representative of three independent experiments. *Po0.05
vs RdB/IL-12. (c) 51Cr-release assay. B16-F10 cells were labeled with 51Cr and incubated with activated T cells isolated from mice treated with Ads at
100:1 E:T ratios. Each data point indicates means±s.e.m. of triplicates of representative of three independent experiments. **Po0.01 vs RdB/IL-12.
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number of IFN-g-secreting immune cells isolated from RdB/IL-12/IL-
18-treated mice at a concentration of 2.5 105 w a sm u c hh i g h e r
(380±74) than cells isolated from PBS- (51±18), RdB- (74±15),
RdB/IL-12- (147±55) or RdB/IL-18-treated mice (85±13) (Figure 5b).
To further delineate the tumor-speciﬁc immune response in vivo,a
51Cr-release assay was carried out. Splenocytes obtained from RdB/
IL-12/IL-18-treated mice showed the most potent B16-F10-speciﬁc
lytic activity on day 3 after exposure. CTL killing of splenocytes from
mice treated with RdB/IL-12, RdB/IL-18 or RdB/IL-12/IL-18 was
32.1±0.5, 10±2.1 and 50.8±0.5, respectively, at an effector-to-target
(E:T) ratio of 100:1, respectively, with no measurable background
(Figure 5c). The CTL activity of splenocytes from mice treated with
RdB/IL-12, RdB/IL-18 or RdB/IL-12/IL-18 was speciﬁc to a given
tumor, as no CTL activity could be detected when NIH3T3 cells were
used as target cells. These results show that RdB/IL-12/IL-18-treated
mice had a higher tumor-speciﬁc adaptive immune response than did
RdB/IL-12- or RdB/IL-18-treated mice.
Figure 6 Histological and immunohistochemical analysis of tumor sections from mice treated with Ads. Ads were injected on days 0, 2 and 4, and tumors
were collected on day 7 for histological analysis. (a) Frozen sections of tumor tissue were then stained by hematoxylin and eosin. Original magniﬁcation:
 40 and  400. Cryosections of tumor tissue were stained with anti-NK-1.1 (b), anti-CD4 (c) and anti-CD8 (d) monoclonal antibodies. Original
magniﬁcation:  100 and  400.
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RdB/IL-12/IL-18-treated tumors
To analyze histological characteristics of tumor tissues following RdB/
IL-12/IL-18 treatment, we performed hematoxylin and eosin staining
of tumor tissues. Histological evaluation of tumor sections revealed
that large areas of tumors treated with RdB/IL-12/IL-18 were necrotic.
In particular, tumors treated with RdB/IL-12 or RdB/IL-12/IL-18 were
extensively inﬁltrated with immune cells, whereas tumors treated with
RdB or RdB/IL-18 showed sparse inﬁltration. Moreover, denser
immune cell inﬁltration was observed not only around, but also inside
the remaining tumor tissues treated with RdB/IL-12/IL-18.
To obtain more insight into the molecular mechanisms of cytokine-
mediated inhibition of tumor growth, we performed immunohisto-
logical analysis. Immunohistochemical studies conﬁrmed that the
tumor-inﬁltrating immune cells were CD4+ T cells, CD8+ T cells
and NK cells. Higher numbers of all three cell types were detected in
wider areas of RdB/IL-12/IL-18-treated tumors than in tumors treated
with either RdB/IL-12 or RdB/IL-18 (Figure 6).
Increased IL-12Rb2o rI L - 1 8 R a expression in RdB/IL-12/IL-18-
treated tumors
To examine whether expression of IL-12Rb2o rI L - 1 8 R a of T cells
could be enhanced in RdB/IL-12/IL-18-treated tumor tissue, we
performed immunoﬂuorescence double staining using anti-CD4,
anti-CD8, anti-IL-12Rb2 and anti-IL-18Ra antibodies. Sections were
prepared from C57BL6 mice 3 days after the ﬁnal virus injection and
Figure 7 Enhancement of T cells expressing IL-12Rb2o rI L - 1 8 R a in tumor tissues. Tumor tissues were harvested from tumor-bearing mice 3 days following
ﬁnal virus treatment. Sections of tumor tissue were incubated with anti-CD4 (Green) plus anti-IL-12Rb2 (Red) (a), anti-CD4 (Green) plus anti-IL-18Ra (Red)
(b), anti-CD8 (Green) plus anti-IL-12Rb2 (Red) (c), and anti-CD8 (Green) plus anti-IL-18Ra (Red) (d). Original magniﬁcation:  400.
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IL-12Rb2o rI L - 1 8 R a. The analysis revealed an elevation in the
number of CD4+ and CD8+ T cells expressing IL-12Rb2o rI L - 1 8 R a
in the tumor tissues of RdB/IL-12/IL-18-treated mice, compared with
those of RdB/IL-12- or RdB/IL-18-treated mice (Figure 7). Effector
T cells have to maintain both IL-12Rb2 and IL-18Ra expression for
differentiating T cells.18 Therefore, these data indicate that RdB/IL-12/
IL-18 treatment resulted in an improved generation of optimally
differentiated T cells expressing IL-12Rb2o rI L - 1 8 R a.
DISCUSSION
Therapeutic manipulation of immune responses by the use of cyto-
kines is potent strategy for cancer immunotherapy and tumor growth
suppression.19 However, the systemic administration of cytokines
at a therapeutic dose can result in serious toxicity in human
cancer-bearing patients as well as in animal cancer models.20,21 Some
patients given IL-12 have even died following treatment.22 Therefore,
it is important to understand as to how to induce therapeutic levels of
cytokines long enough to generate antitumor immunity effectively
within the tumor microenvironment while simultaneously attenuating
systemic toxicity. To address this issue, we have used an E1B-deleted
and E1A-mutated oncolytic Ad, RdB, which exerts an antitumor effect
in a cancer cell-speciﬁc manner as an intratumoral delivery system of
therapeutic cytokines.23 Moreover, this tumor-selective oncolytic
adenoviral vector is competent at killing the tumor cells, as well as
amplifying production of transgenes, by continuously replicating in
tumor cells until the tumor tissues were eradicated.24
Earlier data from our group showed that locally high expression of
IL-12 in the tumor tissues by oncolytic Ad elicited potent antitumor
effects without the induction of adverse effects by an increase in IL-12
Figure 7 Continued.
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IL-18 have a more effective antitumor activity than either cytokine
alone.20,25,26 Several studies have shown that IL-18 and IL-12 syner-
gistically mediate antitumor immunity in a number of animal tumor
models. Oshikawa et al.27 showed that IL-12-, pro-IL-18- and IL-
1b-converting enzyme act synergistically to elicit an enhanced anti-
tumor immune response in a murine mammary adenocarcinoma
model via induction of cytotoxic CD8+ T cells and IFN-g. Similarly,
recombinant IL-12 and IL-18 proteins were shown to signiﬁcantly
inhibit tumor growth and lymph-node metastasis in hepatoma
tumor-bearing guinea-pigs.28 Furthermore, in DC-based tumor
vaccine therapy, DCs co-producing IL-12 and IL-18 induced complete
tumor rejection through the generation of an effective Th1 immune
response in a BALB/c sarcoma model.29
In an effort to augment the efﬁciency of immune gene therapy
in vivo, we explored the potential therapeutic beneﬁt of an oncolytic
Ad co-expressing IL-12 and IL-18. We ﬁrst showed that RdB/IL-12/IL-
18 resulted in not only enhanced and prolonged suppression of tumor
growth and increased survival compared with either RdB/IL-12 or
RdB/IL-18, but also a higher incidence of complete tumor regression
(data not shown), suggesting that RdB/IL-12/IL-18 elicited an
improved antitumor effect than RdB/IL-12 or RdB/IL-18 alone.
To show the underlying mechanism of this enhanced RdB/IL-12/
IL-18-mediated antitumor effect, we next evaluated the characteristics
of RdB/IL-12/IL-18-treated tumor tissues. Surprisingly, in contrast to
our in vitro results, the expression levels of both IL-12 and IL-18 were
markedly elevated in RdB/IL-12/IL-18-treated tumor tissues. More
speciﬁcally, in vivo, RdB/IL-12/IL-18 elicited a 3.7- and 3.5-fold
increase in IL-12 and IL-18 expression, whereas in vitro, RdB/IL-12/
IL-18 elicited a 3.2- and 2.6-fold decrease in IL-12 and IL-18
expression.
IL-18, in concert with IL-12, enhances IFN-g production from
activated T and NK cells.11,14 IFN-g in turn induces DC maturation
and macrophages activation, resulting in the elevation of IL-12 and
IL-18 expression in those cells.18,30 This positive feedback loop could
explain the upregulation of IL-12 and IL-18 in RdB/IL-12/IL-18-
treated tumor tissues. Furthermore, matured DCs and activated
macrophages can themselves produce IFN-g as well as IL-12 and
IL-18.31,32 In accordance with this positive feedback loop, we found
that expression levels of IFN-g, a Th1 cytokine, were considerably
higher in RdB/IL-12/IL-18-treated mice than in RdB/IL-12- or RdB/
IL-18-treated mice (Figure 3c). IFN-g has a signiﬁcant role in boosting
cell-mediated antitumor immune responses by increasing cancer cell
immunogenicity through enhancing antigen presentation as well as
prompting antigen-presenting cells, NK cells, CTLs and Th1 T cells.18
Yang et al.33 have shown that co-administration of IFN-g or IL-12
with the recombinant Ad into the airway of C57BL/6 mice prevents
the activation of Th2 cells and formation of neutralizing antibody,
allowing for efﬁcient re-administration of recombinant Ad. In agree-
ment with such ﬁndings, our study shows that RdB/IL-12/IL-18
generates increased Th1/Th2 cytokine ratio with the upregulation of
IL-12, IL-18, IFN-g and GM-CSF in tumor tissues. Taken together,
these results suggest that RdB/IL-12/IL-18 administered intratumo-
rally may be competent at killing the tumor cells, as well as amplifying
production of cytokines, by continuously replicating in tumor cells
regardless of Ad-speciﬁc neutralizing antibody levels.
GM-CSF expression was also dramatically increased in tumor
tissues treated with RdB/IL-12/IL-18 compared with those treated
with RdB/IL-12 or RdB/IL-18, supporting the importance of IFN-g-
and GM-CSF-mediated antitumor immune response. GM-CSF, a Th1
cytokine, stimulates an antitumor cell-mediated immune response by
facilitating not only the recruitment, maturation and function of DCs,
but also by enhancing the cross-presentation of DCs, which is
important for recognizing tumor cells.34–36 R e c e n t l y ,w es h o w e dt h a t
intratumoral delivery of GM-CSF can promote antigen presentation
and elevate the tumor-speciﬁc CTL response.37 Therefore, we suggest
that upregulation of GM-CSF in the tumor microenvironment may
enhance antigen presentation, leading to the generation of a tumor-
speciﬁc immune response.
Tumor microenvironment has been shown to establish immuno-
suppressive cytokine networks that favor the suppression of an
antitumor immune response and eventually generate tumor prolifera-
tion, angiogenesis and metastasis. Therefore, it is critical to understand
the immunosuppressive environment at the tumor site to manipulate
and generate antitumor immunity effectively within the tumor micro-
environment. To this end, our data suggest that RdB/IL-12/IL-18
generated a tumor microenvironment more favorable to activate
tumor-speciﬁc immune cells via upregulation of IL-12, IL-18, IFN-g
and GM-CSF in tumor tissues. Moreover, the manipulation of a
tumor milieu more favorable to activate tumor-speciﬁc immune cells
by RdB/IL-12/IL-18 was further supported by the observation that
Th1/Th2 cytokine ratio was markedly elevated in RdB/IL-12/IL-18-
treated tumor tissues (Figures 4a and b).
To activate tumor-speciﬁc immune cells, antitumor adaptive immu-
nity in the tumor milieu should be optimally generated. Here, we
showed that mice injected with RdB/IL-12/IL-18 had enhanced CTL
activity, as well as an increase in tumor-speciﬁc IFN-g-secreting
immune cells, than did those given RdB/IL-12 or RdB/IL-18. In
accordance with these results, both histological and immunohisto-
chemical results showed immense necrotic regions as well as inﬁltra-
tion of NK, CD4+ Tand CD8+ T cells into the tumor tissues of RdB/
IL-12/IL-18-treated mice compared with those of RdB/IL-12- or RdB/
IL-18-treated mice. NK cells are known to play an important role in
the promotion of Th1 responses by producing IFN-g and modulating
DC activity.38,39 This observation suggests that IL-12 plus IL-18
activate NK cells that mediate oncolysis and DC maturation that, in
turn, enhance antigen presentation to induce tumor-speciﬁc T cells to
differentiate from naı ¨ve T cells, leading to the generation of antitumor
immunity.
Biological functionality of RdB/IL-12/IL-18-mediated IL-12 and
IL-18 expression in tumor tissues depends on the expression level of
IL-12Rb2 and IL-18Ra. Therefore, upregulation of IL-12Rb2a n d
IL-18Ra correlates with the capacity of IL-12 and IL-18 to bind and
initiate the development of Th1 immunity. Reports from in vitro
studies have shown that IL-18 enhances the production of IL-12Rb2
on T cells, whereas IL-12 mediates upregulation of IL-18Ra on
T cells.40,41 Here, we showed that the numbers of T cells expressing
IL-12Rb2o rI L - 1 8 R a were increased in tumor tissues of RdB/IL-12/
IL-18-treated tumors (Figure 7). Moreover, animals treated with RdB/
IL-12/IL-18 showed an elevated number of CD4+ and CD8+ T cells
expressing IL-12Rb2o rI L - 1 8 R a at the tumor tissues. The expression
of IL-12Rb2o rI L - 1 8 R a receptors are necessary for the differentiation
of effector T cells.18 Therefore, our ﬁnding implies that intratumoral
delivery of IL-12 and IL-18 by RdB/IL-12/IL-18 resulted in improved
generation of optimally differentiated CD4+ and CD8+ T cells expres-
sing IL-12Rb2o rI L - 1 8 R a. Our results further support the view put
forth by Li et al.13 that IL-12, in combination with IL-18, induces
differentiation of the antitumor effector T cells CD4+ and CD8+.
In conclusion, the ﬁnding in our report provides a novel underlying
mechanism of combination therapies via IL-12 and IL-18 that
promotes differentiation of T cells expressing IL-12Rb2 or IL-18Ra.
We also provide the ﬁrst study where intratumoral expression of both
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potent tumor-speciﬁc immunity. These results provide a new insight
into therapeutic mechanisms through IL-12 plus IL-18, as well as a
potential clinical cancer immunotherapeutic agent for the generation
of improved antitumor immunity.
MATERIALS AND METHODS
Cell lines
All cell lines were maintained in Dulbecco’s modiﬁed Eagle’s medium (Gibco
BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum
(Gibco BRL), L-glutamine (2mMl 1), penicillin (100IUml 1)a n ds t r e p t o -
mycin (50mgml  1). All cell lines were cultured at 371C in a humidiﬁed
atmosphere of 5% CO2 and 95% air.
Animal studies
Six- to eight-week-old male C57BL/6 mice were obtained from Charles River
Laboratories International Inc. (Wilmington, MA, USA). During the experi-
ments, all mice were kept in a laminar air ﬂow cabinet under speciﬁc pathogen-
free conditions at Yonsei University College of Medicine, an Association for
Assessment and Accreditation of Laboratory Animal Care-accredited animal
facility. All animal experiments were conducted under the institutional guide-
lines established by the Animal Research Committee.
Generation of Ads expressing IL-12 and IL-18
To generate an oncolytic Ad expressing IL-12 at the E3 region, we ﬁrst
constructed a pSP72-E3 Ad shuttle vector42 expressing murine IL-12 comprised
of p35 and p40. The IL-12 gene (p35/IRES/p40) was digested from pCA14-IL-12
using BglII and subcloned into pSP72-E3 Ad shuttle vector with BamHI,
creating a pSP72-E3-IL-12 E3 shuttle vector. The newly constructed pSP72-E3-
IL-12 E3 shuttle vector was then linearized with NdeI digestion, and RdB23 was
linearized with SpeI digestion. The linearized pSP72-E3-IL-12 E3 shuttle vector
was then co-transformed into Escherichia coli BJ5183 along with the SpeI-
digested RdB for homologous recombination, resulting in RdB/IL-12 oncolytic
Ad. To generate an oncolytic Ad expressing IL-18 at the E3 region, we ﬁrst
constructed an E3 shuttle vector expressing murine IL-18. BglII fragments
containing IL-18 expression cassette were excised from pCA14-IL-18, and
subcloned into pSP72-E3 Ad shuttle vector predigested with BamHI, resulting
in a pSP72-E3-IL-18. The newly constructed pSP72-E3-IL-18 shuttle vector was
then linearized with XmnI digestion, and then co-transformed into E. coli
BJ5183 together with the SpeI-digested RdB for homologous recombination,
creating an RdB/IL-18 oncolytic Ad. To construct an oncolytic Ad-expressing
IL-12 and IL-18 at the E1 and E3 region, respectively, pSP72-E3-IL-18 E3
shuttle vector was then linearized with XmnI digestion, and the Ad vector RdB/
IL-12 was linearized with SpeI digestion. The linearized pSP72-E3-IL-18 E3
shuttle vector was then co-transformed into E. coli BJ5183 along with the SpeI-
digested RdB/IL-123 for homologous recombination, generating an RdB/IL-12/
IL-18 oncolytic Ad. The ratio of plaque-forming unit to viral particle for RdB,
RdB/IL-12, RdB/IL-18 and RdB/IL-12/IL-18 used in this study is 1:42, 1:46,
1:39 and 1:47, respectively.
ELISA for IL-12 and IL-18 expression
To assess IL-12 and IL-18 levels, B16-F10 melanoma cells were plated onto six-
well plates at 5 104 cells per well, and then infected with RdB, RdB/IL-12, RdB/
IL-18 or RdB/IL-12/IL-18 Ad at MOIs of 10–200. At 96h post-infection, the
supernatants were harvested. IL-12 and IL-18 expressionwere determined using
an ELISA according to the manufacturer’s speciﬁcations (IL-12p70 ELISA kit:
Endogen, Woburn, MA, USA; IL-18 ELISA kit: MBL, Nagoya, Japan).
Antitumor effects of oncolytic Ad co-expressing IL-12 plus IL-18
Tumors were implanted subcutaneously on the left abdomen of C57BL/6 mice
by inoculating viable B16-F10 murine melanoma cells (5 105)i n5 0 mlo f
Hank’s balanced salt solution (Gibco BRL). When the average tumor volume
reached 80mm3, mice were randomly divided into one of ﬁve groups (six
animals per group) receiving PBS, RdB, RdB/IL-12, RdB/IL-18 or RdB/IL-12/
IL-18 mixed with Lipofectamine and plus reagent (Gibco BRL) at a 2:6 ratio.
Ads or PBS were injected intratumorally (1 108 plaque-forming unit per
tumor in 30ml of PBS) on days 0, 2 and 4. Control mice were injected with PBS
only. Tumor volume was evaluated once every 2 days by electronic caliper
measure: volume¼0.523LW2 (L¼the length of tumors; W¼the width of
tumors). Tumor responses to each treatment were compared using a log-rank
test analysis (StatView software; Abacus Concepts Inc., Berkeley, CA, USA). The
percentage of surviving mice was determined by monitoring the tumor growth-
related events (tumor size 42500mm3). The survival curve was then plotted
against time after treatment. Differences in survival were considered statistically
signiﬁcant when P-values were o0.01.
Quantiﬁcation of cytokines and Th1/Th2/Th17 proﬁle in tumor
tissue
Tumors were harvested 3 days after the last viral inoculation of the B16-F10
tumor-bearing mice and snap-frozen in liquid nitrogen. Tumor tissues were
homogenized (ART-MICCRA D-8; ART moderne Labortechnik, Munchen,
Germany) in ice-cold radio immunoprecipitation assay buffer (Elipis Biotech,
Taejeon, South Korea) with a proteinase inhibitor cocktail (Sigma, St Louis,
MO, USA). Homogenates were then centrifuged in a high-speed micro-
centrifuge for 10min and determined for total protein content using a BCA
protein assay reagent kit (Pierce, Rockford, IL, USA). Levels of IL-12, IL-18,
IFN-g and GM-CSF in the tumor tissue extract were determined by ELISA
according to the supplier’s recommendations (IL-12 ELISA kit; Endogen, IL-18
ELISA kit; MBL, IFN-g ELISA kit; Endogen, GM-CSF ELISA kit; Endogen). In
addition, Th1/Th2/Th17 type cytokine expression proﬁles in the tumor tissue
extract were estimated using Th1/Th2/Th17 CBA kit (BD Biosciences
PharMingen). ELISA and CBA results were normalized relative to the total
protein concentration in each tumor and were calculated as picograms per
milligram of total protein.
IFN-c ELISPOT assay in splenocytes
At 3 days following the last viral treatment, spleens were obtained aseptically
from tumor-bearing mice, and unicellular splenocytes were prepared as
described previously.3 Prepared spleen cells were co-cultured with irradiated
B16-F10 (5000rad) tumor cells for 3 days in the presence of recombinant
human IL-2 (100Uml 1; R&D Systems, Minneapolis, MN, USA). An IFN-g
ELISPOT assay was then carried out as described previously.3 The spots were
measured with a computer-based immunospot system (AID Elispot Reader
System, version 3.4; Autoimmun Diagnostika GmbH, Strassberg, Germany).
Cytotoxicity assay in splenocytes
The cytolytic activity of tumor-speciﬁc CTL was evaluated by 4h 51Cr-release
assay. Co-cultured spleen cells were prepared as described for the IFN-g
ELISPOT assay. After co-culture, splenocytes as effector cells were recovered
and incubated with 51Cr-labeled B16-F10 or NIH3T3 cells as target cells at
100:1 E:T ratios for 4h at 371Ca n d5 %C O 2. Thereafter, the supernatant was
obtained and 51Cr release was assessed. The percentage of speciﬁc lysis was
calculated by the following formula: ((c.p.m. experimental release c.p.m.
spontaneous release)/(c.p.m. maximum release c.p.m. spontaneous
release)) 100. Spontaneous release was determined by incubation of the
labeled target cells without effector cells. For maximum release, labeled target
cells were treated with detergent.
Histology and immunohistochemistry for NK-1.1, CD4 and CD8
For histological study, tumor tissues were snap-frozen in OCT compound
(Sakura Finetec, Torrance, CA, USA), and 10-mm sections were cut on a
cryostat. Representative sections were stained with hematoxylin and eosin, and
then investigated using light microscopy. To detect lymphocytes, tumor tissues
were snap-frozen in OCT compound (Sakura Finetec), and 10-mm sections
were cut, subjected to immunohistochemistry, and then counterstained with
Meyer’s hematoxylin. The sections were incubated with puriﬁed rat anti-mouse
CD4 monoclonal antibody (BD Biosciences PharMingen), puriﬁed rat anti-
mouse CD8 monoclonal antibody (BD Biosciences PharMingen) or puriﬁed
mouse anti-mouse NK-1.1 monoclonal antibody (Biolegend, San Diego, CA,
USA) as a primary antibodies, and then with goat anti-rat IgG (BD Biosciences
PharMingen) or goat-anti mouse IgG (Southern Biotech, Birmingham,
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(DAKO, Carpinteria, CA, USA) was used as the chromogen substrate.
Immunoﬂuorescence double staining for T cells expressing
IL-12Rb2o rI L - 1 8 R a
For immunoﬂuorescence double staining for CD4+ and CD8+ T cells expres-
sing IL-12Rb2 or IL-18Ra, cryosections were treated with rat anti-mouse CD4
monoclonal antibody (BD Biosciences PharMingen) or rat anti-mouse CD8
monoclonal antibody (BD Biosciences PharMingen) and incubated overnight
at 41C, followed by Alexa ﬂour 488 (Green)-labeled goat anti-rat IgG
(Invitrogen, Carlsbad, CA, USA) at room temperature for 1h. The cryosections
were then incubated with goat anti-IL-12Rb2 polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or rabbit anti-mouse IL-18Ra polyclonal
antibody (Santa Cruz Biotechnology) at 41C overnight and at room tempera-
ture for 1h with Alexa ﬂour 568 (Red)-labeled rabbit anti-goat IgG (Invitro-
gen) or Alexa ﬂour 568 (Red)-labeled goat anti-rabbit IgG (Invitrogen),
respectively. For counterstaining, the samples were incubated with 4,6-diami-
dino-2-phenylindole (Sigma), and then observed by a laser scanning confocal
imaging system (LSM 510-META; Carl Zeiss, Jena, Germany).
Statistical analysis
The data are expressed as mean±s.e. of the mean (s.e.m.). Statistical compar-
ison was made using Stat View software (Abacus Concepts Inc., Berkeley, CA,
USA) and the Mann–Whitney test (non-parametric method). The criterion for
statistical signiﬁcance was Po0.05.
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